Kura Oncology KURA
NASDAQ KURA
$10.86 +0.15 (+1.40%)
As of: Oct 1, 2026 · 10:49 AM EDT

Kura Oncology (KURA) EBITDA Margin (2025 - 2026)

Updated

Kura Oncology (KURA) posted EBITDA Margin of -348.00% for Q2 2026, up 125.85 percentage points from -473.85% a year earlier and up 81.57 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) EBITDA Margin (2025 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Kura Oncology was -394.74%; for FY2025, it was -448.41%, down 91.44 percentage points from FY2024.

  • In prior years, Kura Oncology's EBITDA Margin was -356.97% in FY2024.
  • According to Business Quant data, EBITDA Margin for the three prior quarters was -429.56% (Q1 2026), -462.50% (Q4 2025) and -354.50% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 Kura Oncology 952.70 Mn 952.70 Mn 20.63 Mn -348.00%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -348.00%
Mar 31, 2026 -429.56%
Dec 31, 2025 -462.50%
Sep 30, 2025 -354.50%
Jun 30, 2025 -473.85%
Mar 31, 2025 -456.90%
API Access

Kura Oncology EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KURA&period=max&api_key=YOUR_API_KEY